Press Releases

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests. Plans to continue operations without interruption and it is business-as-usual for the Company in providing service for existing Medicare consumers and partners. CHICAGO, June 07, 2026 (GLOBE NEWSWIRE) -- GoHealth, Inc. ("GoHealth" or the "Company"), a health insurance marketplace and Medicare-focused digital health company, announced that GoHealth and certain of its subsidiaries have voluntarily filed chapter 11 petitions (the

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 ​ Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetesAcross studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic riskINDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced signi

Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney Tunes Land media kit available HERE.LOS ANGELES, June 6, 2026 /PRNewswire/ -- Six Flags Magic Mountain is excited to announce that  Looney Tunes™ Land, a uniquely themed area with loveable characters, is now open. The refreshed family-friendly area has been reimagined where the timeless fun of Looney Tunes™ comes to life. Developed in partnership with Warner Bros. Discovery Global Experiences and designed for young adventurers and families alike, Looney Tunes Land brings together colorful environments, pl

What's happening: Temperatures are forecast to reach the 90s, pushing cooling systems to run longer and use more energy to maintain indoor temperaturesWhy it matters: Acting now with a few simple steps can help reduce energy use during the heat waveCHARLOTTE, N.C., June 6, 2026 /PRNewswire/ -- High temperatures are forecast across the Carolinas this weekend and next week, and Duke Energy has tips to help you take control of your energy use while keeping you and your family cool. Tips to save energy and money Set your thermostat to the highest comfortable setting. Even a couple of degrees can help save energy and money. Keep in

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance  New data expands on findings shared at ATTD and reinforces Eversense 365's strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stag

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesityIn addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1CINDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), tod

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (NASDAQ:AIFA) ("AIFA" or the "Company") today provided a strategic update. Following the Company's previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group ("HyalRoute") and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an "AI infrastructure network powered by optical technologies" and an "AI application services matrix." The Company stated that, on June 5, AIFA Ch

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific

Results from multiple Phase 2b dose finding studies for berobenatide (PF'3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials Pfizer Inc. (NYSE:PFE) today presented detailed results from multiple Phase 2

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet's technology today—it also fuels

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978  Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10 CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential firs

Watch the Official Gameplay Trailer Showcasing a New Take on Turn-Based Tactics Games; Pre-Orders Now Available for PC, PlayStation 5, Xbox Series X|S Electronic Arts Inc. (NASDAQ:EA) today announced that Star Wars Zero Company™, a single-player turn-based tactics game, developed by Bit Reactor in collaboration with Lucasfilm Games, will be available on PC, PlayStation® 5 and Xbox Series X|S starting August 27, 2026. Pre-Orders are now available on all platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605316929/en/Star Wars Zero Company Key Art A new gameplay trailer delivers an action-packed look at the game's grit

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization ACTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on near-patient testing for critical care, today announced the closing of its previously announced private placement for the purchase

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfactionExploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithmsData from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic dis

•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China

NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively.  Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026